U.S. health secretary says agency can eliminate drug rebates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to U.S. health secretary says agency can eliminate drug rebates

Pfizer (PFE), Astellas Pharma Inc. Reports Amendments to Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide

August 22, 2018 5:01 PM EDT

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC). These amendments accelerate timelines for the anticipated primary completion dates of both trials.

ARCHES is a randomized Phase 3 study evaluating the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus ADT alone in metastatic HSPC patients. The primary endpoint of the trial is radiographic progression-free survival (rPFS). Changes to the protocol... More

Bullish Positioning Continues in CVS Health (CVS), Targeting Upside in Shares -Susquehanna

August 22, 2018 1:50 PM EDT

Susquehanna options strategist Alison Edwards notes continued bullish options positioning in CVS Health (NYSE: CVS), as an investor bought 2,500 Oct 75/80 calls spreads for $1.50. Investors are already long 5k of the call spread, as well as long ~10k Oct 75 calls outright.

... More